close icon-linkedin icon-twitter icon-facebook icon-mail icon-google-plus icon-search icon-phone icon-instagram
What are you looking for?
Aleksandra Zwolinksa

Aleksandra Zwolinska

European patent attorney
I am a European patent attorney at NLO’s pharmaceutical sector and my technical background is biotechnology, molecular diagnostics, genetic engineering, and biopharmaceuticals. As a former in-house patent attorney, I enjoy identifying and providing the appropriate IP deliverables in support of the mission and business goals of my client.


  • Antibody
  • Biotechnology
  • Pharma
  • Gene therapy
  • Medical Technology
  • Oligonucleotide
  • Unitary patent
  • Food
  • Medicines

Prior to joining NLO, I worked as an in-house patent attorney in a Belgian oncology-focused MDx company. Consequently, it is natural for me to think of my client’s strategy and needs. I believe that IP portfolios should be tailor-made and evolve dynamically in support of their owners’ business goals and arising opportunities.

    My approach to managing IP is pragmatic, practical, and goal-oriented.

    Before that, I was a scientist primarily focused on molecular oncology. I hold a PhD in biotechnology from Ghent University and worked as a postdoctoral fellow at KUL. Therefore, my scientific expertise includes nucleic acid technologies such as amplification-based detection, sequencing, recombination, genetic engineering, genomics, transcriptomics, bioinformatics, but also proteomics, immunology, and biopharmaceuticals (antibodies, vaccines, cell-based therapies, etc.).

    My approach to managing IP is pragmatic, practical, and goal-oriented. As a former researcher and an inventor on several patents, I am genuinely interested in science and technology. Consequently, I approach my clients’ inventions with great curiosity and enthusiasm. I value direct and honest interaction with my clients and strive to provide them with top-notch IP products in an efficient and adaptable manner.


    •  Ceipi Diploma course: Patent Litigation in Europe, University of Strasbourg, FR (2018)
    •  PhD in Biotechnology,Ghent University, BE (2011)
    •  MSc in Biotechnology, Warsaw University of Life Sciences, PL (2007)


    • Suppression of Myc oncogenic activity by Nucleostemin haploinsufficiency.
      Zwolinska AK, Beekman C, Whiting A, Sedivy J, Marine JC. Oncogene. 2012 Jul 12;31(28):3311-21. doi: 10.1038/onc.2011.507. Epub 2011 Nov 14.
    • MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.
      Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J. EMBO J. 2010 Aug 4;29(15):2538-52. Epub 2010 Jun 29.
    • Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
      Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska AK, Marine JC, Lambrechts D, Suh YA, Rousseau F, Schymkowitz J. Nat Chem Biol. 2011 May;7(5):285-95. Epub 2011 Mar 27.